Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of irAEs With Different Dosing Strategies of Immunotherapies in Solid Tumors
NCT07174453Phase 3Recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and nivolumab in solid tumor (2 arms), sponsored by University of Kansas Medical Center. Primary endpoint: Proportions of grade >=3 immune related adverse events at 12 weeks. Started Oct 2025; status: recruiting.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07174453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174453.